ID: ALA5094648

Max Phase: Preclinical

Molecular Formula: C69H86FN11O12S2

Molecular Weight: 1344.64

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ccc(C[C@@H]2NC(=O)[C@H]([C@@H](C)OC)NC(=O)[C@@H]3[C@@H]4CCN3C(=O)[C@H](Cc3c[nH]c5ccc(F)cc35)NC(=O)[C@H](Cc3cccc(c3)C/C=C\CO4)NC(=O)[C@@H](CN)NC(=O)[C@H](C)NC(=O)CCSCc3cccc(c3)CSCCNC(=O)[C@]3(C)CCCN3C2=O)cc1

Standard InChI:  InChI=1S/C69H86FN11O12S2/c1-41-61(83)78-56(37-71)63(85)75-53-34-45-13-8-12-43(31-45)11-6-7-28-93-57-22-27-80(66(88)55(76-62(53)84)35-48-38-73-52-21-18-49(70)36-51(48)52)60(57)65(87)79-59(42(2)91-4)64(86)77-54(33-44-16-19-50(92-5)20-17-44)67(89)81-26-10-24-69(81,3)68(90)72-25-30-95-40-47-15-9-14-46(32-47)39-94-29-23-58(82)74-41/h6-9,12-21,31-32,36,38,41-42,53-57,59-60,73H,10-11,22-30,33-35,37,39-40,71H2,1-5H3,(H,72,90)(H,74,82)(H,75,85)(H,76,84)(H,77,86)(H,78,83)(H,79,87)/b7-6-/t41-,42+,53-,54-,55-,56+,57-,59-,60-,69-/m0/s1

Standard InChI Key:  NFVSLVJJBHQNIP-KRVBXEOQSA-N

Associated Targets(Human)

Subtilisin/kexin type 9 362 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1344.64Molecular Weight (Monoisotopic): 1343.5883AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, Bianchi E, Branca D, Bueters T, Buist N, Ha SN, Hafey M, He H, Higgins J, Johns DG, Kerekes AD, Koeplinger KA, Kuethe JT, Li N, Murphy B, Orth P, Salowe S, Shahripour A, Tracy R, Wang W, Wu C, Xiong Y, Zokian HJ, Wood HB, Walji A..  (2021)  A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.,  64  (22.0): [PMID:34704436] [10.1021/acs.jmedchem.1c01599]

Source